Cover Image

PP 8.4 - 00061 Bispecific antibodies promote natural killer cell-mediated elimination of the HIV reservoir

Saved in:

Bibliographic Details
Main Authors:	N. Board (Author), F. Wu (Author), M. Moskovljevic (Author), M. Ravi (Author), S. Sengupta (Author), F. Simonetti (Author), L. Montaner (Author), S. Deeks (Author), J. Siliciano (Author), R. Siliciano (Author)
Format:	Book
Published:	Elsevier, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PP 4.8 - 00108 Presentation of cognate antigens by dendritic cells causes stochastic HIV expression
by: M. Moskovljevic, et al.
Published: (2022)

Understanding persistence of the latent reservoir
by: R.F. Siliciano
Published: (2017)

Efforts to eliminate the latent reservoir in resting CD4+ T cells: strategies for curing HIV-1 infection
by: Ya-Chi Ho, et al.
Published: (2015)

Contribution of antigenic exposure to the persistence of HIV-infected CD4 T cells in vivo
by: F. Simonetti, et al.
Published: (2019)

Majority of the latent reservoir resides in CD32a negative CD4+ T cells
by: L.N. Bertagnolli, et al.
Published: (2017)

OA1-1 Impact of vorinostat treatment of non-Hodgkin's lymphoma on HIV-1 latent reservoir
by: A. Capoferri, et al.
Published: (2017)

Measurement and characterization of the latent reservoir for HIV-1 in patients receiving solid organ transplant
by: A. Martin, et al.
Published: (2017)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024)

Tuberculosis - eliminating the latent killer
by: The Lancet Regional Health - Southeast Asia
Published: (2024)

Brief ATI does not alter the size or composition of the latent HIV-1 reservoir
by: K.J. Bar, et al.
Published: (2017)

OP 3.2 - 00056 Clonally expanded HIV-1 proviruses with 5'-Leader defects can give rise to nonsuppressible residual viremia and complicate ART management
by: F. Wu, et al.
Published: (2022)

Bispecific antibodies in cancer immunotherapy
by: Eva Dahlén, et al.
Published: (2018)

Bispecific antibodies for viral immunotherapy
by: Elisabeth K. Nyakatura, et al.
Published: (2017)

PP 3.1 - 00058 Development of a digital PCR assay to profile HIV expression at single-infected-cell resolution
by: F. Dragoni, et al.
Published: (2022)

19 Quantification and correlates of the replication competent HIV-1 latent viral reservoir in a virally suppressed Ugandan population
by: J.L. Prodger, et al.
Published: (2016)

Real-time predictions of reservoir size and rebound time during antiretroviral therapy interruption trials for HIV
by: A.L. Hill, et al.
Published: (2015)

Bispecific Antibodies Progression in Malignant Melanoma
by: Juan Tang, et al.
Published: (2022)

A pivotal decade for bispecific antibodies?
by: Marlena Surowka, et al.
Published: (2024)

Bispecific antibodies: design, therapy, perspectives
by: Sedykh SE, et al.
Published: (2018)

Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024)

Next generation viral outgrowth assays as proxies for classic QVOA to measure HIV-1 reservoir size
by: M. Stone, et al.
Published: (2017)

OP 3.6 - 00023 Effect of HIV-1 infection, viral particle production, and proviral integration site on CD4+ T cell proliferation
by: J. Kufera, et al.
Published: (2022)

HIV antibodies as markers of HIV systemic reservoir and replication activity
by: S.M. Keating, et al.
Published: (2015)

28 Optimised ART and alloBMT to reduce HIV reservoirs
by: Christine M. Durand, et al.
Published: (2017)

Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy
by: M. Peluso, et al.
Published: (2019)

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
by: Camila Ordóñez-Reyes, et al.
Published: (2022)

Rational selection of building blocks for the assembly of bispecific antibodies
by: Danyang Gong, et al.
Published: (2021)

Intein mediated high throughput screening for bispecific antibodies
by: Tim Hofmann, et al.
Published: (2020)

Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma
by: Omar Castaneda-Puglianini, et al.
Published: (2021)

Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody
by: Arthur J. Schick, et al.
Published: (2022)

T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
by: Daisuke Kamakura, et al.
Published: (2021)

Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer
Published: (2023)

Bispecific antibody-derived molecules to target persistent HIV infection
by: Jeffrey L. Nordstrom, et al.
Published: (2022)

Bispecific antibody drug conjugates: Making 1+1>2
by: Yilin Gu, et al.
Published: (2024)

Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy
by: Xiaojing Qin, et al.
Published: (2024)

Bispecific antibodies: a novel approach for targeting prominent biomarkers
by: Akshita Gupta, et al.
Published: (2020)

Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
by: Yanze Sun, et al.
Published: (2023)

The eIg technology to generate Ig-like bispecific antibodies
by: Lennart Kühl, et al.
Published: (2022)

Bispecific Antibodies in Lung Cancer: A State-of-the-Art Review
by: Atulya Aman Khosla, et al.
Published: (2023)

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
by: Luigi Liguori, et al.
Published: (2022)